Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 2/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14312176 | 0.97 | POLB (0.33) | POLBHTTSMN1; SMN2CDK1CDK5 | |
| SCHEMBL14312193 | 0.94 | POLB (0.33) | POLBHTTSMN1; SMN2CDK1CDK5 | |
| SCHEMBL14312280 | 0.86 | POLB (0.34) | POLBHTTSMN1; SMN2 | |
| SCHEMBL14312266 | 0.86 | GAA (0.40) | POLBHTTSMN1; SMN2GAAALDH1A1 | |
| SCHEMBL14312329 | 0.83 | CRHR1 (0.33) | POLBHTT | |
| SCHEMBL14312210 | 0.80 | MAPT (0.40) | POLBHTTSMN1; SMN2CDK1CDK5 | |
| SCHEMBL14236923 | 0.77 | CDK1 (0.37) | CDK1CDK5 | |
| SCHEMBL14312165 | 0.77 | MAPT (0.40) | CDK1CDK5 | |
| SCHEMBL14236888 | 0.76 | ALDH1A1 (0.40) | HTTSMN1; SMN2CDK1CDK5GAA | |
| SCHEMBL14312180 | 0.75 | MAPT (0.36) | CDK1CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987383-B2 | Triazine derivatives and application thereof | NIPPON KASEI CHEMICAL COMPANY LIMITED (JP) | 2015-03-24 | — | — | US | disclosed |
| US-20130023629-A1 | TRIAZINE DERIVATIVES AND APPLICATION THEREOF | SHINRYO CORPORATION (JP) | 2013-01-24 | — | — | US | disclosed |
| EP-2537833-A1 | TRIAZINE DERIVATIVE, AND APPLICATION THEREOF | Nippon Kasei Chemical Company Limited (JP) | 2012-12-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023629-A1 | TRIAZINE DERIVATIVES AND APPLICATION THEREOF | HSPH1, PRDX3, PRXL2A | POLB 2133/4885HTT 2457/4885SMN1; SMN2 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.